Skip to content

Automated 3D (SonoAVC) Versus 2D Ovarian Follicles Assessment in IVF Cycles: a Randomized Controlled Trial

Automated 3D (SonoAVC) vs 2D Ovarian Follicles Assessment in IVF Cycles: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01723267
Enrollment
54
Registered
2012-11-07
Start date
2012-12-31
Completion date
2013-12-31
Last updated
2016-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

IVF, 3D ultrasound, SonoAVC, patients in IVF treatment

Brief summary

Accurate assessment of the size of follicles is important in IVF treatment.Timing of oocyte maturation and subsequent egg collection is largely based on follicle size. An accurate assessment of follicle size and appropriate timing of HCG result in retrieval of more mature oocytes, improved fertilization and higher pregnancy rates. in 3D technology- fter the capturing of a 3D image of an ovary, SonoAVC automatically analyzes the volume dataset, identifies the boundaries of hypoechoic follicles, and provides estimates of their absolute dimensions. These measurements include the largest diameters in three orthogonal planes, the mean follicular diameter (MFD), the volume of the follicle, and the volume-based diameter (d(V)) of the follicle. In the current study the investigators aim to evaluate the use of this automated technique of follicle measurement vs. standard 2D technology on the timing of oocyte maturation and subsequent oocyte retrieval. The investigators speculate that 3D assessment will increase the rate of mature oocyte collection, and eventually will improve other treatment outcomes such as fertilization rate.

Detailed description

Not desired

Interventions

OTHER3D follicles assessment

3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)

OTHER2D follicles assessment

2D ultrasound in IVF treatment (vs 3D ultrasound)

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 39 Years
Healthy volunteers
No

Inclusion criteria

* Age:18-39, cycle number 1-4

Exclusion criteria

* PCOS * Endometriosis * Poor ovarian response * TESA sperm

Design outcomes

Primary

MeasureTime frame
percentage of matured oocytesone IVF cycle (within two weeks)

Secondary

MeasureTime frame
Fertilization rate in ICSIone IVF cycle/ patient (within two weeks)

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026